Terms: = Endocrine gland cancer AND SDHA, SDH2, 6389, ENSG00000073578, FP, P31040, SDHF AND Treatment
59 results:
1. Tff2 defines transit-amplifying pancreatic acinar progenitors that lack regenerative potential and are protective against Kras-driven carcinogenesis.
Jiang Z; Wu F; Laise P; Takayuki T; Na F; Kim W; Kobayashi H; Chang W; Takahashi R; Valenti G; Sunagawa M; White RA; Macchini M; Renz BW; Middelhoff M; Hayakawa Y; Dubeykovskaya ZA; Tan X; Chu TH; Nagar K; Tailor Y; Belin BR; Anand A; Asfaha S; Finlayson MO; Iuga AC; Califano A; Wang TC
Cell Stem Cell; 2023 Aug; 30(8):1091-1109.e7. PubMed ID: 37541213
[TBL] [Abstract] [Full Text] [Related]
2. Genotype-Phenotype Correlations and Clinical Outcomes in 155 Cases of Pheochromocytoma and Paraganglioma.
Wang H; Papachristos AJ; Gill AJ; Clifton-Bligh R; Aniss AM; Glover A; Sywak M; Sidhu SB
World J Surg; 2023 Mar; 47(3):690-698. PubMed ID: 36550325
[TBL] [Abstract] [Full Text] [Related]
3. Current Status and Issues of the Japan Oncofertility Registry.
Shigematsu K; Shimizu C; Furui T; Kataoka S; Kawai K; Kishida T; Kuwahara A; Maeda N; Makino A; Mizunuma N; Morishige KI; Nakajima TE; Ota K; Ono M; Shiga N; Tada Y; Takae S; Tamura N; Watanabe C; Yumura Y; Suzuki N; Takai Y
J Adolesc Young Adult Oncol; 2023 Aug; 12(4):584-591. PubMed ID: 36516123
[No Abstract] [Full Text] [Related]
4. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
[TBL] [Abstract] [Full Text] [Related]
5. Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches.
Kuo MJM; Nazari MA; Jha A; Pacak K
Front Endocrinol (Lausanne); 2022; 13():936178. PubMed ID: 35903274
[TBL] [Abstract] [Full Text] [Related]
6. Paraganglioma and other tumour detection rates in individuals with SDHx pathogenic variants by age of diagnosis and after the age of 50.
Greenberg SE; Holman R; Kohlmann W; Buchmann L; Naumer A
Clin Endocrinol (Oxf); 2021 Sep; 95(3):447-452. PubMed ID: 34255389
[TBL] [Abstract] [Full Text] [Related]
7. Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG).
Geoffron S; Lier A; de Kermadec E; Sermondade N; Varinot J; Thomassin-Naggara I; Bendifallah S; Daraï E; Chabbert-Buffet N; Kolanska K
Gynecol Oncol; 2021 Jun; 161(3):817-824. PubMed ID: 33812696
[TBL] [Abstract] [Full Text] [Related]
8. Targeting STAT3 by a small molecule suppresses pancreatic cancer progression.
Chen H; Bian A; Yang LF; Yin X; Wang J; Ti C; Miao Y; Peng S; Xu S; Liu M; Qiu WW; Yi Z
Oncogene; 2021 Feb; 40(8):1440-1457. PubMed ID: 33420372
[TBL] [Abstract] [Full Text] [Related]
9. Fertility preservation after fertility-sparing surgery in women with borderline ovarian tumours.
Khiat S; Provansal M; Bottin P; Saias-Magnan J; Metzler-Guillemain C; Courbiere B
Eur J Obstet Gynecol Reprod Biol; 2020 Oct; 253():65-70. PubMed ID: 32784054
[TBL] [Abstract] [Full Text] [Related]
10. Pheochromocytoma and paraganglioma: implications of germline mutation investigation for treatment, screening, and surveillance.
Gómez AM; Soares DC; Costa AAB; Pereira DP; Achatz MI; Formiga MN
Arch Endocrinol Metab; 2019 Jul; 63(4):369-375. PubMed ID: 31365623
[TBL] [Abstract] [Full Text] [Related]
11. Pheochromocytoma, paragangliomas, and pituitary adenoma: An unusual association in a patient with an SDHD mutation. Case report.
Lemelin A; Lapoirie M; Abeillon J; Lasolle H; Giraud S; Philouze P; Ceruse P; Raverot G; Vighetto A; Borson-Chazot F
Medicine (Baltimore); 2019 Jul; 98(30):e16594. PubMed ID: 31348302
[TBL] [Abstract] [Full Text] [Related]
12. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
[TBL] [Abstract] [Full Text] [Related]
13. The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma.
Kong G; Schenberg T; Yates CJ; Trainer A; Sachithanandan N; Iravani A; Ravi Kumar A; Hofman MS; Akhurst T; Michael M; Hicks RJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5091-5099. PubMed ID: 30977831
[TBL] [Abstract] [Full Text] [Related]
14. Chemotherapy response of pancreatic cancer by diffusion-weighted imaging (DWI) and intravoxel incoherent motion DWI (IVIM-DWI) in an orthotopic mouse model.
Wu L; Li J; Fu C; Kühn B; Wang X
MAGMA; 2019 Aug; 32(4):501-509. PubMed ID: 30825012
[TBL] [Abstract] [Full Text] [Related]
15. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract] [Full Text] [Related]
16. Malignant paraganglioma and somatotropinoma in a patient with germline SDHB mutation-genetic and clinical features.
Saavedra A; Lima J; Castro L; Silva R; Macedo S; Rodrigues E; Carvalho D
Endocrine; 2019 Jan; 63(1):182-187. PubMed ID: 30155846
[TBL] [Abstract] [Full Text] [Related]
17. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
Abu Hassaan SO
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
[TBL] [Abstract] [Full Text] [Related]
18. PHEOCHROMOCYTOMA: A GENETIC AND DIAGNOSTIC UPDATE.
Mercado-Asis LB; Wolf KI; Jochmanova I; Taïeb D
Endocr Pract; 2018 Jan; 24(1):78-90. PubMed ID: 29144820
[TBL] [Abstract] [Full Text] [Related]
19. Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis.
Mo J; Wang L; Huang X; Lu B; Zou C; Wei L; Chu J; Eggers PK; Chen S; Raston CL; Wu J; Lim LY; Zhao W
Nanoscale; 2017 Sep; 9(35):13142-13152. PubMed ID: 28849826
[TBL] [Abstract] [Full Text] [Related]
20. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
Sonbol MB; Firwana B; Wang Z; Almader-Douglas D; Borad MJ; Makhoul I; Ramanathan RK; Ahn DH; Bekaii-Saab T
Cancer; 2017 Dec; 123(23):4680-4686. PubMed ID: 28817187
[TBL] [Abstract] [Full Text] [Related]
[Next]
